Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.

McBride JW, Malcolm RK, Dias N, Cameron D, Offord RE, Hartley O, Kett VL, Devlin B, Boyd P.

Int J Pharm. 2019 Jun 10;564:207-213. doi: 10.1016/j.ijpharm.2019.04.040. Epub 2019 Apr 15.

PMID:
30999049
2.

Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES.

McBride JW, Boyd P, Dias N, Cameron D, Offord RE, Hartley O, Kett VL, Malcolm RK.

J Control Release. 2019 Mar 28;298:1-11. doi: 10.1016/j.jconrel.2019.02.003. Epub 2019 Feb 4.

3.

Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.

McBride JW, Dias N, Cameron D, Offord RE, Hartley O, Boyd P, Kett VL, Malcolm RK.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00965-17. doi: 10.1128/AAC.00965-17. Print 2017 Oct.

4.

Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.

Wang NX, Sieg SF, Lederman MM, Offord RE, Hartley O, von Recum HA.

Mol Pharm. 2013 Oct 7;10(10):3564-73. doi: 10.1021/mp3007242. Epub 2013 Aug 26.

5.

CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.

Choi WT, Nedellec R, Coetzer M, Colin P, Lagane B, Offord RE, Hartley O, Mosier DE.

J Virol. 2012 Sep;86(18):10218-20. doi: 10.1128/JVI.00353-12. Epub 2012 Jul 11.

6.

Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.

Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE.

PLoS One. 2011;6(7):e22020. doi: 10.1371/journal.pone.0022020. Epub 2011 Jul 8.

7.

"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.

Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE.

J Virol. 2010 Jun;84(11):5842-5. doi: 10.1128/JVI.01907-09. Epub 2010 Mar 24.

8.

Chemokine analogues show suitable stability for development as microbicides.

Cerini F, Landay A, Gichinga C, Lederman MM, Flyckt R, Starks D, Offord RE, Le Gal F, Hartley O.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):472-6. doi: 10.1097/QAI.0b013e31818c953f.

PMID:
18989226
9.

Microbicides and other topical strategies to prevent vaginal transmission of HIV.

Lederman MM, Offord RE, Hartley O.

Nat Rev Immunol. 2006 May;6(5):371-82. Review.

PMID:
16639430
10.

Engineering chemokines to develop optimized HIV inhibitors.

Hartley O, Offord RE.

Curr Protein Pept Sci. 2005 Jun;6(3):207-19. Review.

PMID:
15974948
11.

PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.

Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE, Arts EJ, Zimmerman PA, Blauvelt A.

J Virol. 2004 Jul;78(14):7602-9. Erratum in: J Virol. 2004 Oct;78(19):10837. Bruce, Shannon E [corrected to Bruse, Shannon E].

12.

Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3.

Chvatchko Y, Proudfoot AE, Buser R, Juillard P, Alouani S, Kosco-Vilbois M, Coyle AJ, Nibbs RJ, Graham G, Offord RE, Wells TN.

J Immunol. 2003 Nov 15;171(10):5498-506.

13.

Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.

Hartley O, Dorgham K, Perez-Bercoff D, Cerini F, Heimann A, Gaertner H, Offord RE, Pancino G, Debré P, Gorochov G.

J Virol. 2003 Jun;77(12):6637-44.

14.

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.

Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE.

Antimicrob Agents Chemother. 2003 Feb;47(2):509-17.

15.

Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.

Storto G, Buchegger F, Waibel R, Kuenzi G, Offord RE, Schubiger PA, Gillet M, Delaloye AB.

Cancer Biother Radiopharm. 2001 Oct;16(5):371-9.

PMID:
11776754
16.

Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.

Marozsan AJ, Torre VS, Johnson M, Ball SC, Cross JV, Templeton DJ, Quiñones-Mateu ME, Offord RE, Arts EJ.

J Virol. 2001 Sep;75(18):8624-38.

17.

Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants.

Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, Orenstein JM, Offord RE, Neurath AR, Blauvelt A.

J Exp Med. 2000 Nov 20;192(10):1491-500.

18.

Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.

Rusconi S, La Seta Catamancio S, Citterio P, Bulgheroni E, Croce F, Herrmann SH, Offord RE, Galli M, Hirsch MS.

J Virol. 2000 Oct;74(19):9328-32.

19.

Positive and negative labeling of human proinsulin, insulin, and C-peptide with stable isotopes. New tools for in vivo pharmacokinetic and metabolic studies.

Stöcklin R, Arrighi JF, Hoang-Van K, Vu L, Cerini F, Gilles N, Genet R, Markussen J, Offord RE, Rose K.

Methods Mol Biol. 2000;146:293-315. Review. No abstract available.

PMID:
10948509
20.

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, Offord RE, Quiñones-Mateu ME, Arts EJ.

J Virol. 2000 May;74(10):4868-76.

21.

Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.

Proudfoot AE, Buser R, Borlat F, Alouani S, Soler D, Offord RE, Schröder JM, Power CA, Wells TN.

J Biol Chem. 1999 Nov 5;274(45):32478-85.

22.

Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation.

Rusconi S, La Seta-Catamancio S, Kurtagic S, Galazzi M, Arienti D, Trabattoni D, Wilken J, Thompson DA, Offord RE, Galli M, Clerici M.

AIDS Res Hum Retroviruses. 1999 Jul 1;15(10):861-7.

PMID:
10408722
23.

Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES.

Rusconi S, Merrill DP, La Seta-Catamancio S, Citterio P, Offord RE, Hirsch MS.

AIDS. 1999 Jun 18;13(9):1144-5. No abstract available.

PMID:
10397549
24.

Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, Offord RE, Thompson DA, Wilken J.

J Virol. 1999 May;73(5):3544-50.

25.

Short-term insulin-induced glycogen formation in primary hepatocytes as a screening bioassay for insulin action.

Vu L, Pralong WF, Cerini F, Gjinovci A, Stöcklin R, Rose K, Offord RE, Kippen AD.

Anal Biochem. 1998 Aug 15;262(1):17-22.

PMID:
9735143
26.

Elimination of free radionuclide by a chelating agent improves tumor-to-nontumor ratios following radioimmunotargeting with antibody labeled with 67Ga.

Ryser JE, Rose K, Jones R, Pelegrin A, Donath A, Egeli R, Smith A, Offord RE.

Nucl Med Biol. 1998 Apr;25(3):261-5.

PMID:
9620632
27.
29.

Receptor-mediated endocytosis of CC-chemokines.

Solari R, Offord RE, Remy S, Aubry JP, Wells TN, Whitehorn E, Oung T, Proudfoot AE.

J Biol Chem. 1997 Apr 11;272(15):9617-20.

30.

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TN, Proudfoot AE.

Science. 1997 Apr 11;276(5310):276-9.

31.

Synthesis and evaluation of fluorescent chemokines labeled at the amino terminal.

Offord RE, Gaertner HF, Wells TN, Proudfoot AE.

Methods Enzymol. 1997;287:348-69. No abstract available.

PMID:
9330332
32.

A stable isotope dilution assay for the in vivo determination of insulin levels in humans by mass spectrometry.

Stöcklin R, Vu L, Vadas L, Cerini F, Kippen AD, Offord RE, Rose K.

Diabetes. 1997 Jan;46(1):44-50.

PMID:
8971080
33.
34.

Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist.

Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TN.

J Biol Chem. 1996 Feb 2;271(5):2599-603.

35.

Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins.

Gaertner HF, Offord RE.

Bioconjug Chem. 1996 Jan-Feb;7(1):38-44.

PMID:
8741989
36.

In vitro and in vivo comparison of a randomly coupled antibody fragment-enzyme conjugate with a site-specific conjugate.

Werlen RC, Offord RE, Blakey DC, East SJ, Melton RG, Rose K.

Biomed Pept Proteins Nucleic Acids. 1995;1(5):251-4.

PMID:
9575348
37.

High yield, site-specific coupling of N-terminally modified beta-lactamase to a proteolytically derived single-sulfhydryl murine Fab'.

Mikolajczyk SD, Meyer DL, Starling JJ, Law KL, Rose K, Dufour B, Offord RE.

Bioconjug Chem. 1994 Nov-Dec;5(6):636-46.

PMID:
7873667
38.

Preparation and characterization of novel substrates of insulin proteinase (EC 3.4.99.45).

Werlen RC, Offord RE, Rose K.

Biochem J. 1994 Sep 15;302 ( Pt 3):907-11.

39.

Site-specific conjugation of an enzyme and an antibody fragment.

Werlen RC, Lankinen M, Rose K, Blakey D, Shuttleworth H, Melton R, Offord RE.

Bioconjug Chem. 1994 Sep-Oct;5(5):411-7.

PMID:
7849070
40.

Site-specific religation of G-CSF fragments through a thioether bond.

Gaertner HF, Offord RE, Cotton R, Timms D, Camble R, Rose K.

Bioconjug Chem. 1994 Jul-Aug;5(4):333-8.

PMID:
7524688
41.
42.
43.

Protein conjugates of defined structure: synthesis and use of a new carrier molecule.

Vilaseca LA, Rose K, Werlen R, Meunier A, Offord RE, Nichols CL, Scott WL.

Bioconjug Chem. 1993 Nov-Dec;4(6):515-20.

PMID:
8305521
44.

Facile identification by electrospray mass spectrometry of the insulin fragment A14-21-B17-30 produced by insulin proteinase.

Vu L, Stöcklin R, Rose K, Offord RE.

Rapid Commun Mass Spectrom. 1993 Nov;7(11):1048-50.

PMID:
8280915
45.

Site-specific conjugation of a radioiodinated phenethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor.

Kurth M, Pèlegrin A, Rose K, Offord RE, Pochon S, Mach JP, Buchegger F.

J Med Chem. 1993 Apr 30;36(9):1255-61.

PMID:
8487262
46.

Semisynthesis of human growth hormone-releasing factor by trypsin catalyzed coupling of leucine amide to a C-terminal acid precursor.

Bongers J, Offord RE, Felix AM, Campbell RM, Heimer EP.

Int J Pept Protein Res. 1992 Sep-Oct;40(3-4):268-73.

PMID:
1478784
47.

Construction of protein analogues by site-specific condensation of unprotected fragments.

Gaertner HF, Rose K, Cotton R, Timms D, Camble R, Offord RE.

Bioconjug Chem. 1992 May-Jun;3(3):262-8.

PMID:
1381617
48.

Site-specific modification of a fragment of a chimeric monoclonal antibody using reverse proteolysis.

Fisch I, Künzi G, Rose K, Offord RE.

Bioconjug Chem. 1992 Mar-Apr;3(2):147-53.

PMID:
1515467
49.

Chemical methods of protein synthesis and modification.

Humphries J, Offord RE, Smith RA.

Curr Opin Biotechnol. 1991 Aug;2(4):539-43. Review.

PMID:
1367673
50.

Preparation of well-defined protein conjugates using enzyme-assisted reverse proteolysis.

Rose K, Vilaseca LA, Werlen R, Meunier A, Fisch I, Jones RM, Offord RE.

Bioconjug Chem. 1991 May-Jun;2(3):154-9.

PMID:
1932214

Supplemental Content

Loading ...
Support Center